Conference Proceedings
Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
F Meric-Bernstam, H Arkenau, B Tran, R Bahleda, R Kelley, C Hierro, D Ahn, A Zhu, M Javle, R Winkler, H He, J Huang, L Goyal
Annals of Oncology | Elsevier BV | Published : 2018